Pharma
Alkem Laboratories Ltd
ALKEM · NSE · INE540L01014Thursday, 10 Sept 202612:16 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE18.9%
ROCE21.2%
ROE18.9%
1Y Return-12.3%
Avg. Volume0.1M
Price Chart
52-Week Range
About
Alkem Laboratories Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹5,142.6
52W High / Low₹5,933.5 / ₹5,075
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE18.9%
1Y Return-12.3%
Day Change+0.05%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹15,081 Cr | ₹14,712 Cr | ₹12,965 Cr | ||||||||||
| Expenses | ₹12,049 Cr | ₹11,706 Cr | ₹10,452 Cr | ||||||||||
| Operating Profit | ₹3,032 Cr | ₹3,007 Cr | ₹2,512 Cr | ||||||||||
| OPM % | 20.0% | 20.0% | 19.0% | ||||||||||
| Other Income | ₹412 Cr | ₹407 Cr | ₹494 Cr | ||||||||||
| Depreciation | ₹395 Cr | ₹382 Cr | ₹357 Cr | ||||||||||
| Interest | ₹178 Cr | ₹161 Cr | ₹122 Cr | ||||||||||
| Profit Before Tax | ₹2,872 Cr | ₹2,871 Cr | ₹2,527 Cr | ||||||||||
| Tax | ₹668 Cr | ₹520 Cr | ₹312 Cr | ||||||||||
| Net Profit | ₹2,204 Cr | ₹2,351 Cr | ₹2,215 Cr | ||||||||||
| EPS (₹) | 180.5 | 192.5 | 181.1 | ||||||||||
| Dividend Payout % | — | 28% | 25% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹3,740 Cr | ₹3,603 Cr | ₹3,737 Cr | ₹4,001 Cr | |||||||||
| Expenses | ₹2,974 Cr | ₹3,086 Cr | ₹2,909 Cr | ₹3,080 Cr | |||||||||
| Operating Profit | ₹766 Cr | ₹517 Cr | ₹828 Cr | ₹921 Cr | |||||||||
| OPM % | 20.0% | 14.0% | 22.0% | 23.0% | |||||||||
| Depreciation | ₹100 Cr | ₹106 Cr | ₹95 Cr | ₹94 Cr | |||||||||
| Interest | ₹47 Cr | ₹54 Cr | ₹42 Cr | ₹35 Cr | |||||||||
| Net Profit | ₹521 Cr | ₹251 Cr | ₹653 Cr | ₹779 Cr | |||||||||
| EPS (₹) | 43.5 | 19.8 | 53.2 | 64.0 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹24 Cr | ₹24 Cr | ₹24 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹13,796 Cr | ₹11,961 Cr | ₹10,288 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹2,047 Cr | ₹1,381 Cr | ₹1,418 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹4,991 Cr | ₹4,325 Cr | ₹3,845 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹20,858 Cr | ₹17,691 Cr | ₹15,575 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹3,871 Cr | ₹2,852 Cr | ₹2,873 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,869 Cr | ₹1,846 Cr | ₹484 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹14,836 Cr | ₹12,445 Cr | ₹12,060 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹20,858 Cr | ₹17,691 Cr | ₹15,575 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹1,963 Cr | ₹-1,682 Cr | ₹-503 Cr | ₹-222 Cr |
| FY25 | ₹1,913 Cr | ₹-1,288 Cr | ₹-811 Cr | ₹-186 Cr |
| FY24 | ₹1,948 Cr | ₹-1,011 Cr | ₹-1,145 Cr | ₹-207 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-08Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseBSE Filing2026-08-15Alkem Laboratories Ltd (BOM:539523) (Q1 2027) Earnings Call Highlights: Robust Revenue Growth ...GuruFocus.com2026-08-13Earnings To Watch: Alkem Laboratories Ltd (NSE:ALKEM) Q1 2027 -- GF Value Sees 26% UpsideGuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.